Table 1.

Selected oncolytic viruses in clinical development

Oncolytic virusCancer clinical trials in progressCell surface entry receptor
AdenovirusBladder cancer, ovarian cancer, prostate cancer, head and neck cancer, sarcomas, NSCLC, glioblastomaCoxsackie virus and adenovirus receptor (CAR)
Coxsackie virusMelanoma, breast cancer, prostate cancerCAR, ICAM-1, DAF
HSV-1Melanoma, breast cancer, head and neck cancer, pancreatic cancerHVEM, nectin 1, nectin 2
Measles virusOvarian cancer, glioblastoma, multiple myelomaSLAM and CD46
Newcastle disease virusGlioblastomaType I IFN and Bcl-2
ParvovirusGlioblastomaSialic acid
PoliovirusGlioblastomaCD155
PoxvirusHead and neck cancer, hepatocellular carcinoma, melanoma, colorectal cancerUnknown
ReovirusNSCLC, ovarian cancer, melanoma, head and neck cancerNogo receptor (NgR1) and junctional adhesion molecule A (JAM-A)
Seneca valley virusNeuroblastoma, lung cancerNeuroendocrine featured tumors
Vesicular stomatitis virusHepatocellular carcinomaLow-density lipoprotein receptor (LDLR)

Abbreviation: NSCLC, non–small cell lung cancer.